MRK — Merck & Co., Inc. stock price, charts and financials

QT63Merck & Co., Inc.

Merck & Co., Inc. (NYSE: MRK) is a Healthcare company in the Drug Manufacturers - General industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
130.08
+1.50+1.17%
OverviewShort InterestFilings
MRKQT63Merck & Co., Inc.·NYSE
130.08+1.17%
News
Up 1.2% — The Two Divergent Paths Priced Into Eli Lilly Stock (Yahoo).
Medium confidence
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
NVS+0.28%$156.77AZN+0.79%$162.69ABBV-0.35%$245.18AMGN+0.41%$412.63NVO-0.29%$47.13GILD+0.32%$133.64JNJ+0.32%$260.07PFE+1.10%$27.05
Snapshot
IndexS&P 500, DJIAP/E102.04EPS (ttm)1.26Insider Own0.09%Shs Outstand2.47BPerf Week-1.25%
Market Cap317.54BForward P/E13.40EPS next Y9.59Insider Trans-5.40%Shs Float2.47BPerf Month2.80%
Enterprise Value364.60BPEG-EPS next Q2.27Inst Own76.71%Short Float1.19%Perf Quarter14.49%
Income3.14BP/S4.78EPS this Y-21.78%Inst Trans-Short Ratio2.84Perf Half Y7.37%
Sales66.40BP/B7.61EPS next Y245.46%ROA2.88%Short Interest29.36MPerf YTD22.15%
Book/sh-P/C15.97EPS next 5Y37.35%ROE6.60%52W High136.64 -4.80%Perf Year61.85%
Cash/sh-P/FCF19.77EPS past 3/5Y8.43% 21.23%ROIC7.06%52W Low78.49 65.73%Perf 3Y21.64%
Dividend Est.3.40 (2.61%)EV/EBITDA30.42Sales past 3/5Y3.08% 9.35%Gross Margin75.38%Volatility2.71% 2.46%Perf 5Y67.26%
Dividend TTM3.36 (2.58%)EV/Sales5.49EPS Y/Y TTM-47.33%Oper. Margin17.03%ATR (14)3.31Perf 10Y130.78%
Dividend Ex-DateSep 15, 2026Quick Ratio1.10Sales Y/Y TTM2.22%Profit Margin4.78%RSI (14)54.39Recom2.35
Dividend Gr. 3/5Y5.42% 6.75%Current Ratio1.32EPS Q/Q-157.66%SMA200.56%Beta0.20Target Price140.64
Payout261.52%Debt/Eq1.29Sales Q/Q4.27%SMA503.81%Rel Volume0.63Prev Close128.58
Employees75,000LT Debt/Eq0.90EarningsOct 29SMA20014.11%Avg Volume10.14MPrice130.08
IPO DateJan 13, 1978Option/ShortYes / YesEPS/Sales Surpr.13.15% 2.77%Net Debt/EBITDA3.93Volume6,423,472Change1.17%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-05-26ReiteratedMorgan StanleyEqual Weight$113 → $116
Aug-05-26ReiteratedGuggenheimBuy$145 → $146
Jul-29-26ReiteratedBarclaysOverweight$140 → $150
Jul-27-26ReiteratedBernsteinOutperform$100 → $105
Jul-13-26ReiteratedBMO CapitalOutperform$135 → $142
Jul-13-26ReiteratedGuggenheimBuy$140 → $145
Jul-06-26ReiteratedHSBC$135 → $150
Jun-30-26ReiteratedJefferiesHold$148 → $141
Jun-02-26ReiteratedGuggenheimBuy$122 → $140
May-01-26ReiteratedMorgan StanleyEqual Weight$109 → $112
Latest News
Aug-07-26
Aug-07-2606:38PM
The Two Divergent Paths Priced Into Eli Lilly StockYahoo
01:15AM
These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocksbarrons.com
Aug-06-26
Aug-06-2612:00PM
After Q2 Earnings, Is Pfizer or Merck the Smarter Dividend Play?247wallst.com
10:31AM
Merck (MRK) Is Considered a Good Investment by Brokers: Is That True?zacks.com
06:45AM
U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Seasonbusinesswire.com
Aug-05-26
Aug-05-2611:01AM
MRK Q2 Earnings Call Puts Pipeline Progress in Focuszacks.com
06:04AM
Merck & Co., Inc. Q2 Earnings Call Highlightsmarketbeat.com
Aug-04-26
Aug-04-2604:02PM
Merck & Co Inc (MRK) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic Pipeline Advances Amid One-Time Chargesgurufocus.com
02:46PM
MRK Q2 Earnings & Sales Beat Estimates, '26 Sales View Raisedzacks.com
01:40PM
Merck & Co., Inc. (MRK) Q2 2026 Earnings Call Transcriptseekingalpha.com
11:01AM
Compared to Estimates, Merck (MRK) Q2 Earnings: A Look at Key Metricszacks.com
09:09AM
Stock Futures Surge on Strait of Hormuz Optimismschaeffersresearch.com
08:40AM
Merck (MRK) Reports Q2 Loss, Beats Revenue Estimateszacks.com
06:41AM
Merck Cuts Full-Year Profit Forecast as Acquisition Costs Weigh on Bottom Linewsj.com
06:35AM
Merck posts better-than-expected second-quarter results on Keytruda strengthreuters.com
Company

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

Ownership
Total institutional ownership76.71%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue66,40064,92664,168——————
Cost of Goods Sold Incl. D&A16,35018,19515,193——————
Gross Profit50,05046,73148,975——————
Selling, General and Administrative Excl. Other10,39410,73110,100——————
Research and Development28,35012,51417,938——————
Other Operating Expense00716——————
Operating Income11,30623,48620,221——————
Interest Expense7381,3571,271——————
Unusual Expense
—————————
Non-Operating Income (Expense)-4,620-1,062986——————
Net Income Before Taxes5,94821,06719,936——————
Income Taxes2,7792,8042,803——————
Consolidated Net Income3,17318,25417,117——————
Net Income From Continuing Operations3,17118,26317,133——————
Net Income3,17318,25417,117——————
EPS (Recurring)1.267.306.76——————
EPS (Basic, Before Extraordinaries)1.267.306.76——————
EPS (Diluted)1.257.286.74——————
EBITDA11,98628,26225,706——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio104.0614.4614.76——————
Price To Sales Ratio4.844.063.93——————
Gross Margin75.3871.9876.32——————
Operating Margin17.0336.1731.51——————
Net Margin4.7828.1226.68——————
Shares Outstanding2,4722,5022,532——————
Market Capitalization321,558263,361251,883——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$140.16$122.10$104.03$85.97$67.91● Close Price0.00M7.71M15.42M23.13M30.84MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Guindo ChirfiEVP, Access, Policy & CommsAug 06 '26Sale131.0015,0001,965,00046,613Aug 07
Maraldo David R.EVP & Pres. MMDAug 05 '26Option Exercise82.2518,7061,538,49527,921Aug 07
Williams David MichaelEVP,Chief Info&Digital OfficerAug 05 '26Option Exercise74.4952,8473,936,37766,421Aug 07
Maraldo David R.EVP & Pres. MMDAug 05 '26Sale128.722,686345,73618,212Aug 07
Williams David MichaelEVP,Chief Info&Digital OfficerAug 05 '26Sale128.7734,7054,468,98731,716Aug 07
Maraldo David R.EVP & Pres. MMDMay 02 '26Option Exercise112.1655261,91218,371May 05
Smart Dalton E. IIISVP Fin. - Global ControllerMay 02 '26Option Exercise112.1638342,9579,520May 05
Smart Dalton E. IIISVP Fin. - Global ControllerApr 30 '26Option Exercise110.9546451,4819,296May 01
Larson Betty DEVP, Chief HR OfficerApr 30 '26Option Exercise110.9511,3501,259,28318,917May 01
Smart Dalton E. IIISVP Fin. - Global ControllerApr 29 '26Option Exercise110.03944103,8689,156May 01
Li Dean YExecutive VP & President, MRLApr 29 '26Option Exercise110.034,722519,56296,757May 01
Zachary JenniferEVP, General CounselApr 29 '26Option Exercise110.032,951324,69972,351May 01
Larson Betty DEVP, Chief HR OfficerApr 29 '26Option Exercise110.032,085229,4138,282May 01
Litchfield CarolineEVP & CFOApr 29 '26Option Exercise110.033,935432,96894,239May 01
Davis Robert MChairman, CEO & PresidentApr 29 '26Option Exercise110.0313,3001,463,399456,902May 01
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.